Transzonular intravitreal injection eases treatment burden after cataract surgery
Compounded formulation prevents infection, inflammation, cystoid macular edema
Investigators published their findings in Current Opinion in Ophthalmology (2017;28:73-80).
Most eyes (96.3%) were treated with one injection of TMV intraoperatively; 56 (3.6%) eyes needed a second injection; and one (0.1%) needed a third injection. No major complications developed; seven (0.45%) needed to undergo an unplanned vitrectomy.
In addition, no zonular disruption, hyphema, vitreous hemorrhages, retinal tears of detachments developed. Isolated cases of iris prolapse developed as a result of overfilling of the chamber with the viscoelastic and four cases of spontaneously resolving ciliary body hemorrhage were reported by the authors.
No additional medications were needed postoperatively in almost 92% of eyes. Breakthrough inflammation developed in 9.2% of eyes, visually relevant CME in 2.0% of eyes, and clinically relevant IOP increases in 0.9%.
“The rates of infection and inflammation reported in this retrospective review of a transzonular injection of TMV for prophylaxis after cataract surgery appear similar to reported rates with alternative prophylactic therapies such as topical drops,” Dr. Tyson said. “The transzonular injection of TMV may have advantages in terms of patient compliance.”
This study showed that almost 92% of eyes did not need additional medication postoperatively following the prophylactic transzonular intravitreal injection of TMV.
Dr. Tyson said, “TMV is an advanced technology prophylactic drug that can potentially change the postoperative cataract care paradigm.”